These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 16452533)

  • 1. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
    Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
    Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The German ACROSTUDY: past and present.
    Buchfelder M; Schlaffer S; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Strasburger CJ;
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S3-S10. PubMed ID: 19684061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience from the German pegvisomant observational study.
    Strasburger CJ; Buchfelder M; Droste M; Mann K; Stalla GK; Saller B;
    Horm Res; 2007; 68 Suppl 5():70-3. PubMed ID: 18174713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
    Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
    Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.
    Schreiber I; Buchfelder M; Droste M; Forssmann K; Mann K; Saller B; Strasburger CJ;
    Eur J Endocrinol; 2007 Jan; 156(1):75-82. PubMed ID: 17218728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
    Brue T; Castinetti F; Lundgren F; Koltowska-Häggström M; Petrossians P;
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S11-7. PubMed ID: 19684051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
    van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
    J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
    Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
    Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term experience of pegvisomant therapy as a treatment for acromegaly.
    Higham CE; Chung TT; Lawrance J; Drake WM; Trainer PJ
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):86-91. PubMed ID: 19018786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
    Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
    Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.
    Feenstra J; van Aken MO; de Herder WW; Feelders RA; van der Lely AJ
    Eur J Endocrinol; 2006 Jun; 154(6):805-6. PubMed ID: 16728538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
    Neggers SJ; Franck SE; de Rooij FW; Dallenga AH; Poublon RM; Feelders RA; Janssen JA; Buchfelder M; Hofland LJ; Jørgensen JO; van der Lely AJ
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3644-52. PubMed ID: 24937542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
    Yamaguchi H; Shimatsu A; Okayama A; Sato T
    Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
    Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ
    Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACROSTUDY: the first 5 years.
    Trainer PJ
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S19-24. PubMed ID: 19684052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly.
    Shimatsu A; Nagashima M; Hashigaki S; Ohki N; Chihara K
    Endocr J; 2016 Apr; 63(4):337-47. PubMed ID: 26796763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.